Biopharma/Biotech Analysts Chen & Kim and Biotech Analyst Kluska, along with KOL speakers Dr. Dahiya, Asssoc Prof at University of Maryland and Dr. Ruella, Asst Prof at University of Pennsylvania discuss how next-generation CAR-T therapies could expand the market opportunity for these companies’ treatments, including NVS, GILD, BMY, JNJ, GRCL, PSTX, PGEN, MBIO, ACLX, ALLO, FATE and HARP on an Analyst/Industry conference call to be held on December 14 at 1 pm. Webcast Link
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVS:
- Novartis reports Phase 3 APPLY-PNH trial met both primary endpoints
- Novartis’ (NYSE:NVS) Advanced Prostate Cancer Therapy Bags EU Approval
- Biotech Alert: Searches spiking for these stocks today
- Clovis files for Chapter 11 protection, enters agreement to sell FAP-228
- Erasca Slides After Public Offering; Inks Licensing Deal with NVS